NAS:AMGN (USA) Also Trade In: Argentina Austria Brazil Chile Germany Hongkong Italy Mexico Switzerland UK
Amgen Inc $ 258.24 3.12 (1.22%)
Warning! GuruFocus has detected 4 Medium warning signs with AMGN. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Amgen (AMGN) from 1990 to Jul 05 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Amgen stock (AMGN) PE ratio as of Jul 05 2020 is 20.24. More Details
Amgen PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Amgen PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NYSE:BMY NYSE:LLY NYSE:ABBV NAS:GILD NYSE:MRK NYSE:AGN NYSE:PFE NAS:BIIB NAS:HZNP OTCPK:GWPRF NYSE:JNJ XSWX:ROG XSWX:NOVN LSE:AZN XPAR:SAN LSE:GSK TSE:4519 FRA:A60 XTER:BAYN SHSE:600276
Traded in other countries AMGN.Argentina AMGN.Austria AMGN34.Brazil AMGN.Chile AMG.Germany 04332.Hongkong AMGN.Italy AMG N.Mexico AMGN.Switzerland 0R0T.UK AMGN.USA
Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).